Page 6 - Upstream Processing News Today

Aceto expands GMP product lines for biopharmaceutical and vaccine manufacturing with acquisition of A&C Bio Buffer, growing its manufacturing footprint and strengthening its presence in Europe.

Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.

Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.

Boehringer Ingelheim has inaugurated a state-of-the-art biopharmaceutical production facility in Vienna, Austria: representing the single largest investment in the company’s history.

Moderna will build a state-of-the-art mRNA facility in Africa, with the goal of producing up to 500 million vaccine doses a year.

The company opens the 130,000-square-foot facility, with manufacturing planned to begin later this year.

The new facility will be home to Precision NanoSystems’s new global headquarters and include multiple GMP suites for manufacturing RNA therapeutics and vaccines.

Moderna has signed a Memorandum of Understanding with the government of Canada to build a mRNA vaccine manufacturing facility in the country: which could serve as a model for similar partnerships around the world.

Nkarta and Sana Biotechnology have each leased space in California to support their cell therapy manufacturing plans.

June 25, 2021 published at 2:40 AMACN Newswire Seoul, Korea, June 25, 2021 - (ACN Newswire) - Avantor, a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies and applied materials industries, was named best company in bioprocessing excellence for single-use solutions and best bioprocessing supplier for upstream processing at Biologics Manufacturing Korea (BMK) 2021. Sang Kyu Lee, Representative Director - Avantor Korea/Jap...